Sid JainSVP, Clinical Development & Data Science, Recursion
live WEBINAR
A new era of Biopharma R&D: The TechBio revolution – Realities and the next frontier
Wednesday, November 19, 2025
8 AM PT / 10 AM CT / 11 AM ET
REGISTER NOW
All registrants will be sent the webinar recording shortly following the completion of the session.
what you’ll learn
Join leaders from Tempus and Recursion for a candid discussion on their strategic partnership, which integrates petabytes of multimodal data with AI and supercomputing to advance drug discovery and development at scale. This webinar will explore the scientific, as well as the operational realities of the techbio approach, its impact to date, and how it is helping to shape the road ahead for biopharma R&D.
In this webinar, you will learn how the partnership:
- Integrates Tempus’ multimodal data with Recursion’s high-throughput screening to ground experimental findings and validate therapeutic targets
- Translates insights from real-world data into actionable therapeutic strategies, from preclinical discovery to clinical trial design and execution
- Addresses operational hurdles in unifying disparate data and leverages key learnings to drive the next wave of what’s possible in techbio
SPEAKERS
READ BIO
Sid leads the Clinical Development and Data Science function at Recursion, overseeing Computational Biology, Decision Science, and Biometrics to drive the industrialization of clinical trials through AI-driven patient selection, protocol optimization, and full-scale trial execution. His team integrates multi-omics modeling, real-world data (RWD), and AI/ML applications to optimize clinical trial design, accelerate execution, and generate high-quality regulatory-grade evidence. This includes data-driven patient matching, site selection and engagement, as well as CMC and supply chain (CSC) planning and forecasting, ensuring trials are both efficient and scalable.
Hayley Donnella, PhD Senior Director, Computational Oncology, Recursion
READ BIO
Hayley is the VP of Frontier Research at Recursion, leading a skunkworks-style innovation group building the next generation of AI-native drug discovery technologies. From multimodal data integration and causal AI/ML to bespoke foundation models, we develop novel capabilities that expand the Recursion OS and reimagine how therapeutics are discovered and developed.
MODERATOR
Shane Woods, PhDChief Strategy Officer, Tempus
READ BIO
Shane Woods serves as Chief Strategy Officer at Tempus, where he is responsible for accelerating strategic customer partnerships and incubating new business ventures. With two decades of experience in oncology, Shane has a proven track record of growth and innovation. Shane is a scientist by training, having completed research appointments in cancer biology at academic institutions, including Harvard Medical School and the University of Notre Dame. Shane earned a doctorate in genetics from the University of Cambridge, where he was a Bill Gates Scholar, and graduated with honors in biochemistry from Queen’s University in Canada.
